Prognosis of CRT-treated and CRT-untreated unselected population with LBBB in Stockholm County
- PMID: 37403689
- PMCID: PMC10365846
- DOI: 10.1093/europace/euad192
Prognosis of CRT-treated and CRT-untreated unselected population with LBBB in Stockholm County
Abstract
Aims: Left bundle branch block (LBBB) might be the first finding of cardiovascular diseases but also the prerequisite for cardiac resynchronization therapy (CRT) in heart failure (HF) with reduced ejection fraction (HFrEF). The prognosis for patients with LBBB and the implications of CRT in an unselected real-world setting are the focus of our study.
Methods and results: A central electrocardiogram (ECG) database and national registers have been screened to identify patients with LBBB. Predictors of HF and the use of CRT were identified with Cox models. The hazard ratios (HRs) of death, cardiovascular death (CVD), and HF hospitalization (HFH) were estimated according to CRT use. Of 5359 patients with LBBB and QRS > 150 ms, median age 76 years, 36% were female. At the time of index ECG, 41% had a previous history of HF and 27% developed HF. Among 1053 patients with a class I indication for CRT, only 60% received CRT with a median delay of 137 days, and it was associated with a lower risk of death [HR: 0.45, 95% confidence interval (CI): 0.36-0.57], CVD (HR: 0.47, 95% CI: 0.35-0.63), and HFH (HR: 0.56, 95% CI: 0.48-0.66). The age of over 75 years and the diagnosis of dementia and chronic obstructive pulmonary disease were predictors of CRT non-use, while having a pacing/defibrillator device independently predicted CRT use.
Conclusion: In an unselected LBBB population, CRT is underused but of great value for HF patients. Therefore, it is crucial to find ways of better implementing and understanding CRT utilization and characteristics that influence the management of our patients.
Keywords: CRT; Heart failure; LBBB.
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: P.G. reports no conflict of interest related to this work. S.L. reports no conflict of interest related to this work. I.K. reports no conflict of interest related to this work. A.A. reports no conflict of interest related to this work. G.S. reports research support from Vifor Pharma, Cytokinetics, Boehringer Ingelheim, Boston Scientific, AstraZeneca, Novartis, Merck, Pharmacosmos, Bayer, and Horizon 2022 funding; consulting fees from TEVA, MIUR (Ministero dell’Istruzione, Universita´ e Ricerca), Medical Education Global Solutions, Atheneum, Genesis, Vifor Pharma, and Agence Recherche (ANR); payment or honoraria from Servier, Roche, Cytokinetics, Translational Medicine Academy Foundation (TMA), Medtronic, Medical Education Global Solutions, Dynamicom Education, AstraZeneca, Vifor Pharma, and Novartis; and participation in Advisory Board for AstraZeneca, Edwards, Uppsala Clinical Research Center (UCR), Vifor, and Servier, all outside the present work. M.A. reports no conflict of interest related to this work. C.L. reports receiving research support from the Swedish Heart Lung Foundation, Swedish Royal Society of Science, and Stockholm County Council; consulting fees from AstraZeneca and Roche Diagnostics; and speaker honoraria from Novartis, Astra, Bayer, Vifor Pharma, Medtronic, and Impulse Dynamics and serves on advisory boards for Astra Zeneca, all outside the present work. F.G. reports no conflict of interest related to this work
Figures
Comment on
-
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care.Europace. 2021 Aug 6;23(8):1324-1342. doi: 10.1093/europace/euaa411. Europace. 2021. PMID: 34037728
References
-
- Søndergaard MM, Riis J, Bodker KW, Hansen SM, Nielsen J, Graff Cet al. Associations between left bundle branch block with different PR intervals, QRS durations, heart rates and the risk of heart failure: a register-based cohort study using ECG data from the primary care setting. Open Heart 2021;8:e001425. - PMC - PubMed
-
- Schneider JF, Thomas HE, Kreger BE, McNamara PM, Kannel WB. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med 1979;90:303–10. - PubMed
-
- Rasmussen PV, Skov MW, Ghouse J, Pietersen A, Hansen SM, Torp-Pedersen Cet al. Clinical implications of electrocardiographic bundle branch block in primary care. Heart 2019;105:1160–7. - PubMed
-
- Vaillant C, Martins RP, Donal E, Leclercq C, Thébault C, Behar Net al. Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy. J Am Coll Cardiol 2013;61:1089–95. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
